Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment

Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy has been mostly applied to patients with untreated peripheral T cell lymphoma (PTCL). Because the long-term outcome of patients with PTCL, especially those achieving complete response (CR), has not been fully...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2017-03, Vol.96 (3), p.411-420
Main Authors: Kitahara, Hideaki, Maruyama, Dai, Maeshima, Akiko Miyagi, Makita, Shinichi, Miyamoto, Ken-ichi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Kobayashi, Yukio, Tajima, Kinuko, Terauchi, Takashi, Kurihara, Hiroaki, Taniguchi, Hirokazu, Komatsu, Norio, Tobinai, Kensei
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Cyclophosphamide - administration & dosage
Disease-Free Survival
Doxorubicin - administration & dosage
Female
Follow-Up Studies
Hematology
Hematopoietic Stem Cell Transplantation - trends
Humans
Lymphoma, T-Cell, Peripheral - diagnostic imaging
Lymphoma, T-Cell, Peripheral - therapy
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Prednisone - administration & dosage
Prognosis
Retrospective Studies
Transplantation, Autologous - trends
Treatment Outcome
Vincristine - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy has been mostly applied to patients with untreated peripheral T cell lymphoma (PTCL). Because the long-term outcome of patients with PTCL, especially those achieving complete response (CR), has not been fully elucidated, we retrospectively analyzed 78 consecutive patients initially treated with CHOP/CHOP-like chemotherapy, without high-dose chemotherapy followed by autologous stem cell transplantation (HDC/auto-SCT). Median overall and progression-free survivals in all 78 patients were 44 and 17 months, respectively, with a median follow-up of 62 months. In the 53 patients achieving CR, the median relapse-free survival (RFS) was 21 months, and 2-, 3-, and 5-year RFSs were 46, 45, and 36%, respectively. Although our results showed an unfavorable outcome for PTCL as a whole, those who achieved CR following CHOP/CHOP-like chemotherapy did not always have a poor outcome without the consolidation of HDC/auto-SCT; in particular, 45% of the 65 years or younger patients were alive without disease at 5 years.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-016-2891-8